Harmon Cyrus's Form 4 filing
Olema Pharmaceuticals, Inc. (OLMA) · filed Dec 11, 2024
- Accession no.
- 0001415889-24-029028
- Filed
- Dec 11, 2024
- Trade date
- Dec 9-11, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 0 derivative transactions. Open-market sales total $148.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Harmon CyrusCIK 0001831410 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 9, 2024 | Common Stock | AGrant or awardAcquired | +29,250 | $0.00 | $0 | 780,533 | Direct | |
| Dec 10, 2024 | Common Stock | SSaleDisposed | −8,256 | $9.37 | −$77,358.72 | 772,277 | Direct | |
| Dec 11, 2024 | Common Stock | SSaleDisposed | −7,958 | $8.66 | −$68,916.28 | 764,319 | Direct | |
| Dec 11, 2024 | Common Stock | SSaleDisposed | −179 | $9.39 | −$1,680.81 | 764,140 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.